Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc
Animal Models and Experimental Medicine · 2024
DOI: 10.1002/ame2.12370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2024. Verfasst von Ke Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Aurora Kinase B, Bile Duct Neoplasms, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cholangiocarcinoma (CCA), a malignancy that arises from biliary epithelial cells, has a dismal prognosis, and few targeted therapies are available. Aurora B, a key mitotic regulator, has been reported to be involved in the progression of various tumors, yet its role in CCA is still unclarified.
Methods
Human CCA tissues and murine spontaneous CCA models were used to assess Aurora B expression in CCA. A loss‐of‐function model was constructed in CCA cells to determine the role of Aurora B in CCA progression. Subcutaneous and liver orthotopic xenograft models were used to assess the therapeutic potential of Aurora B inhibitors in CCA.
Results
In murine spontaneous CCA models, Aurora B was significantly upregulated. Elevated Aurora B expression was also observed in 62.3% of human specimens in our validation cohort (143 CCA specimens), and high Aurora B expression was positively correlated with pathological parameters of tumors and poor survival. Knockdown of Aurora B by siRNA and heteroduplex oligonucleotide (HDO) or an Aurora B kinase inhibitor (AZD1152) significantly suppressed CCA progression via G2/M arrest induction. An interaction between Aurora B and c‐Myc was found in CCA cells. Targeting Aurora B significantly reduced this interaction and accelerated the proteasomal degradation of c‐Myc, suggesting that Aurora B promoted the malignant properties of CCA by stabilizing c‐Myc. Furthermore, sequential application of AZD1152 or Aurora B HDO drastically improved the efficacy of gemcitabine in CCA.
Conclusions
Aurora B plays an essential role in CCA progression by modulating c‐Myc stability and represents a new target for treatment and chemosensitization in CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Jinan University, Guangzhou, China.
- Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou, China.
- School of Medicine, Jinan University, Guangzhou, China.
ORCID-Profile: Guohua Cheng
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Liu, K., Zhou, X., Huang, F., Liu, L., Xu, Z., Gao, C., Zhang, K., Hong, J., Yao, N., & Cheng, G. (2024). Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12370
Vancouver
Liu K, Zhou X, Huang F, Liu L, Xu Z, Gao C, et al. Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc. Animal Models and Experimental Medicine. 2024. doi:10.1002/ame2.12370
BibTeX
@article{Liu2024,
author = {Liu, Ke and Zhou, Xuxuan and Huang, Fei and Liu, Lihao and Xu, Zijian and Gao, Chongqing and Zhang, Keke and Hong, Jian and Yao, Nan and Cheng, Guohua},
title = {Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc},
journal = {Animal Models and Experimental Medicine},
year = {2024},
doi = {10.1002/ame2.12370}
}
EUVIMED